Kailera Therapeutics, Inc. SEC filings KLRA
Kailera Therapeutics, Inc. has 64 filings in SEC EDGAR's recent list, going back to Dec 19, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 4, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 4, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 4, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 4, 2026 | Nov 4, 2026 |
| 4 | Insider transaction | Sep 9, 2026 | Sep 7, 2026 |
| 3 | Initial insider ownership | Sep 9, 2026 | Aug 31, 2026 |
| SCHEDULE 13G | Ownership over 5% (passive) | Aug 14, 2026 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | Aug 14, 2026 | — |
| 10-Q | Quarterly report | Aug 12, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 12, 2026 | Aug 12, 2026 |
| SCHEDULE 13G | Ownership over 5% (passive) | Aug 5, 2026 | — |
| 4 | Insider transaction | Jul 8, 2026 | Jul 6, 2026 |
| 3 | Initial insider ownership | Jul 8, 2026 | Jun 29, 2026 |
| 4 | Insider transaction | Jun 11, 2026 | Jun 9, 2026 |
| 10-Q | Quarterly report | May 26, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations
|
May 26, 2026 | May 26, 2026 |
| SCHEDULE 13D | Ownership over 5% (active) | Apr 23, 2026 | — |
| SCHEDULE 13D | Ownership over 5% (active) | Apr 23, 2026 | — |
| 4 | Insider transaction | Apr 22, 2026 | Apr 20, 2026 |
| 4 | Insider transaction | Apr 22, 2026 | Apr 20, 2026 |
| 4 | Insider transaction | Apr 20, 2026 | Apr 20, 2026 |
| 4 | Insider transaction | Apr 20, 2026 | Apr 16, 2026 |
| 4 | Insider transaction | Apr 20, 2026 | Apr 20, 2026 |
| 4 | Insider transaction | Apr 20, 2026 | Apr 16, 2026 |
| 4 | Insider transaction | Apr 20, 2026 | Apr 16, 2026 |
| 4 | Insider transaction | Apr 20, 2026 | Apr 16, 2026 |
| 4 | Insider transaction | Apr 20, 2026 | Apr 16, 2026 |
| 4 | Insider transaction | Apr 20, 2026 | Apr 16, 2026 |
| 4 | Insider transaction | Apr 20, 2026 | Apr 16, 2026 |
| 4 | Insider transaction | Apr 20, 2026 | Apr 16, 2026 |
| 4 | Insider transaction | Apr 20, 2026 | Apr 16, 2026 |
| 4 | Insider transaction | Apr 20, 2026 | Apr 16, 2026 |
| 4 | Insider transaction | Apr 20, 2026 | Apr 16, 2026 |
| 4 | Insider transaction | Apr 20, 2026 | Apr 16, 2026 |
| 4 | Insider transaction | Apr 20, 2026 | Apr 16, 2026 |
| 8-K |
Current report
Bylaw or fiscal year change, Other events
|
Apr 20, 2026 | Apr 20, 2026 |
| 424B4 | Prospectus | Apr 17, 2026 | — |
| S-8 | Employee stock plan registration | Apr 17, 2026 | — |
| EFFECT | Filing | Apr 16, 2026 | — |
| 3 | Initial insider ownership | Apr 16, 2026 | Apr 16, 2026 |
| 3 | Initial insider ownership | Apr 16, 2026 | Apr 16, 2026 |
| 3 | Initial insider ownership | Apr 16, 2026 | Apr 16, 2026 |
| 3 | Initial insider ownership | Apr 16, 2026 | Apr 16, 2026 |
| 3 | Initial insider ownership | Apr 16, 2026 | Apr 16, 2026 |
| 3 | Initial insider ownership | Apr 16, 2026 | Apr 16, 2026 |
| 3 | Initial insider ownership | Apr 16, 2026 | Apr 16, 2026 |
| 3 | Initial insider ownership | Apr 16, 2026 | Apr 16, 2026 |
| 3 | Initial insider ownership | Apr 16, 2026 | Apr 16, 2026 |
| 3 | Initial insider ownership | Apr 16, 2026 | Apr 16, 2026 |
| 3 | Initial insider ownership | Apr 16, 2026 | Apr 16, 2026 |
| 3 | Initial insider ownership | Apr 16, 2026 | Apr 16, 2026 |
| 3 | Initial insider ownership | Apr 16, 2026 | Apr 16, 2026 |
| 3 | Initial insider ownership | Apr 16, 2026 | Apr 16, 2026 |
| 3 | Initial insider ownership | Apr 16, 2026 | Apr 16, 2026 |
| 3 | Initial insider ownership | Apr 16, 2026 | Apr 16, 2026 |
| 3 | Initial insider ownership | Apr 16, 2026 | Apr 16, 2026 |
| 3 | Initial insider ownership | Apr 16, 2026 | Apr 16, 2026 |
| S-1MEF | Filing | Apr 16, 2026 | — |
| 3 | Initial insider ownership | Apr 16, 2026 | Apr 16, 2026 |
| 3 | Initial insider ownership | Apr 16, 2026 | Apr 16, 2026 |
| CERT | Filing | Apr 15, 2026 | — |
| 8-A12B | Filing | Apr 14, 2026 | — |
| S-1/A | Amended registration statement | Apr 13, 2026 | — |
| S-1 | Registration statement | Mar 27, 2026 | — |
| DRS/A | Filing | Feb 11, 2026 | — |
| DRS | Filing | Dec 19, 2025 | — |
Showing 64 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- KLRA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Waltham, MA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 2096997
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.